Winifred M Lo1, Meghan L Good1, Naris Nilubol2, Nancy D Perrier3, Dhaval T Patel4. 1. Thoracic and GI Oncology Branch, National Cancer Institute, Bethesda, MD, USA. 2. Endocrine Oncology Branch, National Institutes of Health, Center for Cancer Research, 10 Center Drive, Building 10/CRC 4 W-5950, Bethesda, MD, USA. 3. Section of Surgical Endocrinology, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Endocrine Oncology Branch, National Institutes of Health, Center for Cancer Research, 10 Center Drive, Building 10/CRC 4 W-5950, Bethesda, MD, USA. dhaval.patel@nih.gov.
Abstract
BACKGROUND: The incidence of parathyroid carcinoma is reported to be rising. There is minimal data on prognostic variables associated with cancer-specific survival. The objectives of this study were to evaluate the trends in incidence and assess prognostic factors. METHODS: A retrospective review of the SEER database between 1973 and 2014 was performed, identifying 520 patients with parathyroid carcinoma. Population-adjusted incidence rates were calculated in 4-year intervals. A Cochrane-Armitage test was performed to analyze changes in trend in incidence, tumor size, and extent of disease. Age, year of diagnosis, race, gender, extent of disease, surgical resection, treatment with radiation, tumor size, and lymph node status were assessed using Mantel-Cox log rank test. Multivariate analysis was performed by Cox regression analysis. RESULTS: The incidence of parathyroid carcinoma has been increasing since 1974 from 2 to 11 cases per 10 million people but has since stabilized at 11 cases per 10 million people since 2001. The increasing incidence was attributed to locoregional disease and tumor size < 3 cm. The presence of metastatic disease [hazard ratio (HR) 111.4, 95% confidence interval (CI) 20.6-601.8, p < 0.0001) and tumor size > 3 cm (HR 5.6, 95% CI 1.5-21.2, p = 0.011] were associated with worse cancer-specific survival by univariate and multivariate analyses. CONCLUSIONS: The incidence of parathyroid carcinoma has remained stable over the past decade. Tumor size < 3 cm and regional disease have increased in incidence. Patients with metastatic disease and tumors > 3 cm have worse cancer-specific survival. These findings can be incorporated in the development of a staging system for parathyroid carcinoma.
BACKGROUND: The incidence of parathyroid carcinoma is reported to be rising. There is minimal data on prognostic variables associated with cancer-specific survival. The objectives of this study were to evaluate the trends in incidence and assess prognostic factors. METHODS: A retrospective review of the SEER database between 1973 and 2014 was performed, identifying 520 patients with parathyroid carcinoma. Population-adjusted incidence rates were calculated in 4-year intervals. A Cochrane-Armitage test was performed to analyze changes in trend in incidence, tumor size, and extent of disease. Age, year of diagnosis, race, gender, extent of disease, surgical resection, treatment with radiation, tumor size, and lymph node status were assessed using Mantel-Cox log rank test. Multivariate analysis was performed by Cox regression analysis. RESULTS: The incidence of parathyroid carcinoma has been increasing since 1974 from 2 to 11 cases per 10 million people but has since stabilized at 11 cases per 10 million people since 2001. The increasing incidence was attributed to locoregional disease and tumor size < 3 cm. The presence of metastatic disease [hazard ratio (HR) 111.4, 95% confidence interval (CI) 20.6-601.8, p < 0.0001) and tumor size > 3 cm (HR 5.6, 95% CI 1.5-21.2, p = 0.011] were associated with worse cancer-specific survival by univariate and multivariate analyses. CONCLUSIONS: The incidence of parathyroid carcinoma has remained stable over the past decade. Tumor size < 3 cm and regional disease have increased in incidence. Patients with metastatic disease and tumors > 3 cm have worse cancer-specific survival. These findings can be incorporated in the development of a staging system for parathyroid carcinoma.
Authors: Randall P Owen; Carl E Silver; Phillip K Pellitteri; Ashok R Shaha; Kenneth O Devaney; Jochen A Werner; Alessandra Rinaldo; Alfio Ferlito Journal: Head Neck Date: 2011-03 Impact factor: 3.147
Authors: Claire Sadler; Kenneth W Gow; Elizabeth A Beierle; John J Doski; Monica Langer; Jed G Nuchtern; Sanjeev A Vasudevan; Melanie Goldfarb Journal: Surgery Date: 2014-11-11 Impact factor: 3.982
Authors: Elliot A Asare; Cord Sturgeon; David J Winchester; Lei Liu; Bryan Palis; Nancy D Perrier; Douglas B Evans; David P Winchester; Tracy S Wang Journal: Ann Surg Oncol Date: 2015-06-16 Impact factor: 5.344
Authors: Scott M Wilhelm; Tracy S Wang; Daniel T Ruan; James A Lee; Sylvia L Asa; Quan-Yang Duh; Gerard M Doherty; Miguel F Herrera; Janice L Pasieka; Nancy D Perrier; Shonni J Silverberg; Carmen C Solórzano; Cord Sturgeon; Mitchell E Tublin; Robert Udelsman; Sally E Carty Journal: JAMA Surg Date: 2016-10-01 Impact factor: 14.766
Authors: Jesús Villar-del-Moral; Antonio Jiménez-García; Pilar Salvador-Egea; Juan M Martos-Martínez; José M Nuño-Vázquez-Garza; Mario Serradilla-Martín; Angel Gómez-Palacios; Pablo Moreno-Llorente; Joaquín Ortega-Serrano; Aitor de la Quintana-Basarrate Journal: Surgery Date: 2014-10-17 Impact factor: 3.982
Authors: Jessica Limberg; Dessislava Stefanova; Timothy M Ullmann; Jessica W Thiesmeyer; Sarina Bains; Toni Beninato; Rasa Zarnegar; Thomas J Fahey; Brendan M Finnerty Journal: Ann Surg Oncol Date: 2020-07-13 Impact factor: 5.344
Authors: Sara Storvall; Eeva Ryhänen; Ilkka Heiskanen; Tiina Vesterinen; Frank V Bensch; Jukka Schildt; Soili Kytölä; Auli Karhu; Johanna Arola; Camilla Schalin-Jäntti Journal: J Endocr Soc Date: 2019-07-23
Authors: Shravan Leonard-Murali; Tommy Ivanics; David S Kwon; Xiaoxia Han; Christopher P Steffes; Rupen Shah Journal: Eur J Surg Oncol Date: 2021-06-27 Impact factor: 4.424